Regulation of APOC1: Potential Drug Target and Biomarker for Cardiovascular Disease

Target Name: APOC1

NCBI ID: G341

APOC1

Regulation of APOC1: Potential Drug Target and Biomarker for Cardiovascular Disease

APOC1 (Apolipoprotein C-I (isoform b)) is a protein that is expressed in various tissues throughout the body, including the liver, heart, kidneys, and blood vessels. It is a member of the APC (Apolipoprotein) family, which is a group of proteins that are involved in the transport of lipids and other molecules in the body.

One of the key functions of APOC1 is its role in the transport of low-density lipoprotein (LDL) cholesterol, which is a major risk factor for the development of heart disease. APOC1 helps to transport LDL cholesterol from the liver to the bloodstream, where it is then delivered to the muscles and tissues for energy production.

In addition to its role in cholesterol transport, APOC1 is also involved in the regulation of inflammation in the body. It has been shown to play a key role in the production of pro-inflammatory cytokines, which can contribute to the development of inflammation in various tissues.

Despite its important functions, the regulation of APOC1 has been the subject of much research in recent years, and it has become an attractive target for drug development. One of the main reasons for this is the growing interest in developing new treatments for cardiovascular disease, which is a leading cause of death and disability in the world.

In addition to its potential as a drug target, APOC1 is also a potential biomarker for the development of cardiovascular disease. The level of APOC1 in the bloodstream has been shown to be a useful indicator of an individual's risk of heart disease, with higher levels of APOC1 being associated with an increased risk of cardiovascular disease.

Another potential use for APOC1 is its role in the regulation of cellular processes in the body. It has been shown to play a key role in the production of various signaling molecules, including angiotensin II and nitric oxide. These molecules are involved in the regulation of blood pressure, blood flow, and other important physiological processes.

Overall, the regulation of APOC1 is an important area of research, with potential implications for the development of new treatments for cardiovascular disease and other conditions. While more research is needed to fully understand the role of APOC1 in these processes, it is clear that it is an important protein that has the potential to contribute to a wide range of biological processes in the body.

Protein Name: Apolipoprotein C1

Functions: Inhibitor of lipoprotein binding to the low density lipoprotein (LDL) receptor, LDL receptor-related protein, and very low density lipoprotein (VLDL) receptor. Associates with high density lipoproteins (HDL) and the triacylglycerol-rich lipoproteins in the plasma and makes up about 10% of the protein of the VLDL and 2% of that of HDL. Appears to interfere directly with fatty acid uptake and is also the major plasma inhibitor of cholesteryl ester transfer protein (CETP). Binds free fatty acids and reduces their intracellular esterification. Modulates the interaction of APOE with beta-migrating VLDL and inhibits binding of beta-VLDL to the LDL receptor-related protein

The "APOC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about APOC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets